910649-32-0
910649-32-0
Chemical Structure
Anrukinzumab
Synonym(s): IMA-638
- CAS No.: 910649-32-0
- Formula:N/A
- Molecular Weight:(145.38 kDa)
SMILES: [Anrukinzumab]
Biological Activity: Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Anrukinzumab | 98.64% | Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Bree A, et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol. 2007 May;119(5):1251-7. [Content Brief]
- [2]. Reinisch W, et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut. 2015 Jun;64(6):894-900. [Content Brief]
- [3]. Elias JA, et al. IL-13 in asthma. The successful integration of lessons from mice and humans. Am J Respir Crit Care Med. 2011 Apr 15;183(8):957-8. [Content Brief]
